Cardioprotective effects of 20(S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Wang, Hongbo ^a   Yu, Pengfei ^a   Gou, Haitao ^b   Zhang, Jianqiao ^a   Zhu, Mei ^a   Wang, Zhen Hua ^b   Tian, Jing Wei ^a,b   Jiang, Yong Tao ^a,b   Fu, Feng Hua ^a  

^a YANTAI UNIVERSITY   (China)

^b Luye Pharma Group Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GINSENOSIDE RH 2; MALONALDEHYDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENZYME RELEASE; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84868691844     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/506214     Document Type: Article

References (25)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 2004 56 2 185 229 2-s2.0-2642566088 10.1124/pr.56.2.6 (Pubitemid 38720829)
2. Scott J. M., Khakoo A., Mackey J. R., Haykowsky M. J., Douglas P. S., Jones L. W., Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation 2011 124 5 642 650
3. Li L., Lu Q., Shen Y., Hu X., Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochemical Pharmacology 2006 71 5 584 595 2-s2.0-31044456677 10.1016/j.bcp.2005.11.026 (Pubitemid 43121992)
4. Arunachalam S., Kim S. Y., Lee S. H., Lee Y. H., Kim M. S., Yun B. S., Yi H. K., Hwang P. H., Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo. Journal of Natural Medicines 2012 66 1 149 157 10.1007/s11418-011-0567-1
5. Olson R. D., Mushlin P. S., Brenner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek R. J. Jr, Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proceedings of the National Academy of Sciences of the United States of America 1988 85 10 3585 3589 2-s2.0-0013228058
6. Li N., Pan Q., Han W., Liu Z., Hu X., Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clinical Cancer Research 2007 13 22 6753 6760 2-s2.0-36749096845 10.1158/1078-0432.CCR-07-1579 (Pubitemid 350206813)
7. Zhu W., Soonpaa M. H., Chen H., Shen W., Payne R. M., Liechty E. A., Caldwell R. L., Shou W., Field L. J., Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009 119 1 99 106 2-s2.0-59049091824 10.1161/ CIRCULATIONAHA.108.799700
8. Li K., Sung R. Y. T., Wei Z. H., Yang M., Nga H. P., Shuk M. L., Wood Y. C., Zhao H., Man Y. T., Tai F. F., Chi K. L., Yuek O. W., Pak C. N., Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006 113 18 2211 2220 2-s2.0-33646819975 10.1161/CIRCULATIONAHA.105.560250
9. Imondi A. R., Della Torre P., Mazué G., Sullivan T. M., Robbins T. L., Hagerman L. M., Podestà A., Pinciroli G., Dose-response relationship of dexrazoxane for prevention of doxorubicin- induced cardiotoxicity in mice, rats, and dogs. Cancer Research 1996 56 18 4200 4204 2-s2.0-0029829953 (Pubitemid 26305016)
10. Siveski-Iliskovic N., Kaul N., Singal P. K., Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994 89 6 2829 2835 2-s2.0-0028275840 (Pubitemid 24173705)
11. Xiao J., Sun G. B., Sun B., Wu Y., He L., Wang X., Chen R. C., Cao L., Ren X. Y., Sun X. B., Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. Toxicology 2012 292 1 53 62 10.1016/j.tox.2011.11.018
12. Karmazyn M., Moey M., Gan X. T., Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs 2011 71 15 1989 2008
13. Attele A. S., Wu J. A., Yuan C. S., Ginseng pharmacology: multiple constituents and multiple actions. Biochemical Pharmacology 1999 58 11 1685 1693 2-s2.0-0344549853 10.1016/S0006-2952(99)00212-9 (Pubitemid 29505408)
14. Schibilsky D., Beyersdorf F., Goebel U., Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. Journal of Heart and Lung Transplantation 2010 29 12 1442 2-s2.0-78649319846 10.1016/j.healun.2010.07.009
15. Kupriyanov V. V., Xiang B., Sun J., Jilkina O., The effects of drugs modulating K+ transport on Rb+ uptake and distribution in pig hearts following regional ischemia: 87Rb MRI study. NMR in Biomedicine 2002 15 5 348 355 2-s2.0-0036668652 10.1002/nbm.777 (Pubitemid 34960102)
16. Zhu D., Wu L., Li C. R., Wang X. W., Ma Y. J., Zhong Z. Y., Zhao H. B., Cui J., Xun S. F., Huang X. L., Zhou Z., Wang S. Q., Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. Journal of Cellular Biochemistry 2009 108 1 117 124 2-s2.0-69249148258 10.1002/jcb.22233
17. Zhang J., Zhou F., Wu X., Zhang X., Chen Y., Zha B. S., Niu F., Lu M., Hao G., Sun Y., Sun J., Peng Y., Wang G., Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells. British Journal of Pharmacology 2012 165 1 120 134 10.1111/j.1476-5381. 2011.01505.x
18. Li B., Zhao J., Wang C. Z., Searle J., He T. C., Yuan C. S., Du W., Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Letters 2011 301 2 185 192 2-s2.0-78651445610 10.1016/j.canlet.2010.11.015
19. Park E. K., Lee E. J., Lee S. H., Koo K. H., Sung J. Y., Hwang E. H., Park J. H., Kim C. W., Jeong K. C., Park B. K., Kim Y. N., Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt. British Journal of Pharmacology 2010 160 5 1212 1223 2-s2.0-77953222632 10.1111/j.1476-5381.2010.00768.x
20. Park E. K., Choo M. K., Oh J. K., Ryu J. H., Kim D. H., Ginsenoside Rh2 reduces ischemic brain injury in rats. Biological and Pharmaceutical Bulletin 2004 27 3 433 436 2-s2.0-4544352951 10.1248/bpb.27.433 (Pubitemid 41685495)
21. Wang H., Li H., Zuo M., Zhang Y., Liu H., Fang W., Chen X., Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Letters 2008 268 1 89 97 2-s2.0-48149092967 10.1016/j.canlet.2008.03.051
22. Rajadurai M., Stanely Mainzen Prince P., Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicology 2007 230 2-3 178 188 2-s2.0-33846197152 10.1016/j.tox.2006.11.053 (Pubitemid 46109139)
23. Sun X., Zhou Z., Kang Y. J., Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Research 2001 61 8 3382 3387 2-s2.0-0035870265 (Pubitemid 32695029)
24. Shi R., Huang C. C., Aronstam R. S., Ercal N., Martin A., Huang Y. W., N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacology 2009 9 7 2-s2.0-65449119946 10.1186/1471-2210-9-7
25. Hellmann K., Overview and historical development of dexrazoxane. Seminars in Oncology 1998 25 4, supplement 10 48 54 2-s2.0-0031713738 (Pubitemid 28460384)